Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa
The original release is unavailable here.
Earlier from TRON
- PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
- Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Triapine
- TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement
- TRON Group Announces Entertainment Rights Acquisition
- TRON Group Announces Partnership with Legend 3D for Visual Effects Services and Education
Later from TRON
- Nanopharmaceutics, Inc. (TGRP) Changes Corporate Name back to TRON Group, Inc. and forms wholly-owned Nanopharmaceutics Subsidiary
- Nanopharmaceutics Announces Initiation of Clinical Study of Oral Tetrathiomolybdate Capsules in Breast Cancer Patients
- PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels
- TRON Group Inc. Announces Results of 2025 Annual Meeting of Shareholders
- Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma
Follow TRON into a list and get an email when it puts out news.
Follow TRON